American Association for Cancer Research--96th Annual Meeting. Anticancer agents-part I.
Phillips
Tom
T
Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London W1T 4JE, UK. tom.phillips@thomson.com
Collins
Tracey
T
Davies
Jamie
J
D015067:17-Hydroxysteroid Dehydrogenases / Q000037:antagonists & inhibitors; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D008863:Microspheres; D009369:Neoplasms / Q000188:drug therapy*; D051058:Oncogene Protein v-akt; D017027:Protein Tyrosine Phosphatases / Q000008:administration & dosage / Q000037:antagonists & inhibitors; D015682:Retroviridae Proteins, Oncogenic / Q000037:antagonists & inhibitors; D043823:Taxoids / Q000627:therapeutic use; D014807:Vitamin D / Q000031:analogs & derivatives
D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D004791:Enzyme Inhibitors; D015682:Retroviridae Proteins, Oncogenic; D043823:Taxoids; D014807:Vitamin D; C080625:taxane; D015067:17-Hydroxysteroid Dehydrogenases; D051058:Oncogene Protein v-akt; D017027:Protein Tyrosine Phosphatases